PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Dabigatran etexilate - VTE prevention post hip/knee replacement

PAD Profile : Dabigatran etexilate - VTE prevention post hip/knee replacement

Keywords :
NOAC, anticoagulant cards, anticoagulant alert cards
Brand Names Include :
Pradaxa

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Capsules
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
01 June 2016
Surrey Medicines Commissioners Group
Surrey Medicines Commissioning Group recommend that patients prescribed all types of anticoagulants (warfarin and NOACs) should be given an anticoagulant alert card to carry with them. For patients taking NOACs, the card should be annotated on the reverse in the “Therapeutic range (INR)” box with the words “not applicable” or “not required for this drug”. The cards are available for practices to order through usual NHS stationery supply routes. See an example of the Anticoagulant Alert Card in the document below
20 May 2009
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The committee confirmed that dabigatran should be considered a hospital only RED drug for the prevention of venous thromboembolism after total hip or total knee replacement in adults

Associated BNF Codes

02. Cardiovascular System
02.08.02. Oral anticoagulants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More